Newsroom
Cyprus’ Health Ministry has introduced a new preventive treatment for respiratory syncytial virus (RSV), aiming to cut hospital admissions among infants and young children during the upcoming winter season.
Health Minister Michalis Damianos announced Friday that the monoclonal antibody nirsevimab (Beyfortus) will now be available through the state health system (GESY). Unlike a vaccine, the drug provides immediate, targeted protection against RSV, a virus that health officials say is the leading cause of pediatric hospital and intensive care admissions in Cyprus.
“With the introduction of nirsevimab, we are strengthening prevention, reducing the risk of serious complications and limiting hospitalizations, especially in ICUs,” Damianos said at a press conference outlining the ministry’s autumn-winter action plan.
The ministry said the decision was based on international evidence showing the treatment is safe and effective. By preventing severe RSV cases, officials expect the program to not only protect vulnerable children but also relieve pressure on hospitals and lower the financial burden of costly admissions.
The new initiative comes alongside continued campaigns for flu and COVID-19 vaccination, with authorities urging high-risk groups to get immunized. Damianos stressed that this year the health system enters the winter season “more prepared and with more tools at its disposal.”
RSV typically causes cold-like symptoms but can lead to severe respiratory illness in babies. Officials said the rollout of nirsevimab marks a critical step in reducing the virus’s impact on families and the health system alike.
